Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 316 AL 330

Computer-Based Drug Design of Positive Modulators of Store-Operated Calcium Channels to Prevent Synaptic Dysfunction in Alzheimer's Disease

Hunanyan L, Ghamaryan V, Makichyan A, Popugaeva E.

Int J Mol Sci. 2021 Dec 19;22(24):13618. doi: 10.3390/ijms222413618.

Probiotics for Alzheimer's Disease: A Systematic Review

Naomi R, Embong H, Othman F, Ghazi HF, Maruthey N, Bahari H.

Nutrients. 2021 Dec 22;14(1):20. doi: 10.3390/nu14010020.

Neurotrophic factors in Alzheimer's disease: pathogenesis and therapy

Lübke JH, Idoon F, Mohasel-Roodi M, Alipour F, Hami J, Ehteshampour A, Mostafaee H, Sadeghi A.

Acta Neurobiol Exp (Wars). 2021;81(4):314-327.

Could Mental and Physical Exercise Alleviate Alzheimer's Disease?

Radić B, Blažeković A, Duraković D, Jurišić-Kvesić A, Bilić E, Borovečki F.

Psychiatr Danub. 2021 Spring-Summer;33(Suppl 4):1267-1273.

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease

Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y, Stauffer S, Li L, Pieper AA, Cummings J, Cheng F.

Nat Aging. 2021 Dec;1(12):1175-1188. doi: 10.1038/s43587-021-00138-z. Epub 2021 Dec 6.

Aducanumab and the FDA - where are we now?

Fillit H, Green A.

Nat Rev Neurol. 2021 Mar;17(3):129-130. doi: 10.1038/s41582-020-00454-9.

Aspirin in people with dementia, long-term benefits, and harms: a systematic review

Davis KAS, Bishara D, Molokhia M, Mueller C, Perera G, Stewart RJ.

Eur J Clin Pharmacol. 2021 Jul;77(7):943-954. doi: 10.1007/s00228-021-03089-x. Epub 2021 Jan 22.

Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study

Nakanishi M, Igarashi A, Ueda K, Brnabic AJM, Matsumura T, Meguro K, Yamada M, Mimura M, Arai H, Treuer T.

Curr Med Res Opin. 2021 Aug;37(8):1331-1339. doi: 10.1080/03007995.2021.1922369. Epub 2021 May 20.

Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation

Lehmann L, Lo A, Knox KM, Barker-Haliski M.

Neurochem Res. 2021 Aug;46(8):1895-1912. doi: 10.1007/s11064-021-03332-y. Epub 2021 Apr 30.

Facilitators, Challenges, and Messaging Strategies for Hispanic/Latino Populations Participating in Alzheimer's Disease and Related Dementias Clinical Research: A Literature Review

Massett HA, Mitchell AK, Alley L, Simoneau E, Burke P, Han SH, Gallop-Goodman G, McGowan M.

J Alzheimers Dis. 2021;82(1):107-127. doi: 10.3233/JAD-201463.

Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities

Toljan K, Homolak J.

Handb Clin Neurol. 2021;179:285-300. doi: 10.1016/B978-0-12-819975-6.00018-2.

The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1

de la Torre JC, Gonzalez-Lima F.

J Alzheimers Dis. 2021;82(3):881-882. doi: 10.3233/JAD-210736.

The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA

Karlawish J, Grill JD.

Nat Rev Neurol. 2021 Sep;17(9):523-524. doi: 10.1038/s41582-021-00540-6.

The Present State of Lithium for the Prevention of Dementia Related to Alzheimer's Dementia in Clinical and Epidemiological Studies: A Critical Review

Ishii N, Terao T, Hirakawa H.

Int J Environ Res Public Health. 2021 Jul 22;18(15):7756. doi: 10.3390/ijerph18157756.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias